Better Stock to Buy Right Now: Coca-Cola (KO) vs. Altria (MO)

Analysts forecast Coca-Cola EPS to grow at a 6.6% CAGR from 2025–2028 versus Altria's 12.5% CAGR; Coca-Cola trades at ~24x forward earnings while Altria trades at ~12x. Coca-Cola offers a forward yield of ~2.7% and has raised dividends for 64 consecutive years; Altria yields ~6.4%, has raised dividends 60 times over 56 years, and targets at least $5B in smoke‑free revenue by 2028 (over a quarter of projected sales). The author prefers Altria due to stronger projected growth, lower valuation, higher yield, and its accelerating smoke‑free product expansion.

Analysis

Altria's push into smoke‑free products is not just a category shift; it's a distribution and regulatory play that leverages an unrivaled U.S. retail footprint. If NJOY and pouch penetration scale through existing C‑store and pharmacy channels, Altria can convert a large part of former cigarette margin to higher‑growth, lower‑taxed SKUs while squeezing out smaller independents who lack shelf access. That dynamic benefits Altria and raises barriers to entry for pure‑play nicotine challengers, but it also concentrates execution risk in commercialization (store placement, youth‑use optics) rather than basic R&D.

For beverage incumbents, portfolio mix changes toward bottled water, energy, and smaller SKU formats transfer margin volatility upstream to PET resin, cap, and cold‑chain logistics suppliers. Container deposit laws and rising recycling compliance will compress netbacks faster than headline revenue shifts imply; bottlers with scale and vertical integration will capture most of the margin transition. Expect a 3–12 month window where packaging suppliers and regional bottlers reprice contracts and pass costs to brand owners unevenly, creating transient winners and losers within the supply chain.

Key catalysts to monitor are regulatory decisions (FDA denial/approval of specific smoke‑free SKUs), state tax/vaping restrictions, and near‑term commodity moves in PET/resin linked to crude. A successful commercial ramp for smoke‑free in the next 12–24 months materially derisks Altria’s legacy decline, while adverse FDA rulings or intensified youth‑use litigation could reverse gains quickly. On timelines: retail share gains show in POS data within 6–12 months; regulatory and litigation outcomes can flip the trade in 3–18 months, so hedge timing matters.

Key Decisions for Investors

• Initiate a small core long in Altria (MO) — 0.25% NAV position sized for income exposure; pair with a 12‑month 12–15% OTM protective put to cap downside. Rationale: asymmetric carry + optionality on successful smoke‑free commercialization; exit or trim if MO outperforms peers by >20% within 9 months.
• Relative value pair: long MO / short PM (equal notional, 12–24 month horizon) sized 0.25% NAV each. Rationale: US retail execution advantage should compound faster than international gains; risk is regulatory correlation — add a 6–12 month collar if FDA headlines turn negative.
• Income harvest: sell 90–120 day covered calls on an existing MO allocation at ~10% OTM to monetize near‑term income expectations while keeping directional exposure. If MO gaps down >15% on adverse news, close the call and reassess with a protective put.
• Tactical risk‑off hedge: trim 10–20% of short‑duration high‑beta tech exposure (eg NVDA) and redeploy into MO over days–weeks if breadth weakens. Rationale: rotation into dividend defensives tends to accelerate on macro volatility; pay attention to AI momentum reversals that would make this trade costly.